Seres Therapeutics Inc. (MCRB)
0.68
0.00 (0.56%)
At close: Apr 02, 2025, 3:59 PM
0.67
-1.73%
After-hours: Apr 02, 2025, 07:51 PM EDT
Seres Therapeutics Income Statement
Financials in USD. Fiscal year
is
January - December.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 |
| Revenue | n/a | 126.33M | 7.13M | 144.93M | 33.22M | 34.51M | 28.27M | 32.1M | 21.77M | n/a | n/a | n/a | n/a |
| Cost of Revenue | n/a | 704K | 1M | 1.73M | 90.57M | 80.14M | 95.95M | 89.45M | 81.99M | 728K | 10.72M | n/a | n/a |
| Gross Profit | n/a | 125.62M | 6.12M | 143.19M | -57.35M | -45.64M | -67.69M | -57.35M | -60.22M | -728K | -10.72M | n/a | n/a |
| Operating Income | -121.31M | -107.98M | -246.49M | -64.49M | -88.13M | -71.88M | -100.28M | -91.39M | -92.84M | -54.86M | -15.08M | -6.05M | -3.03M |
| Interest Income | 3.97M | 7.3M | 3.06M | 2.87M | 946K | 1.03M | n/a | n/a | 2.23M | 638K | n/a | n/a | n/a |
| Pretax Income | 136K | -113.72M | -250.16M | -65.58M | -89.13M | -70.28M | -98.94M | -89.38M | -91.58M | -54.78M | -16.71M | -6.1M | -3.13M |
| Net Income | 136K | -113.72M | -253.82M | -61.5M | -86.45M | -64.24M | -98.94M | -89.38M | -91.58M | -54.78M | -16.71M | -6.1M | -3.13M |
| Selling & General & Admin | 53.18M | 87.74M | 79.69M | 69.26M | 30.77M | 24.75M | 32.6M | 34.04M | 32.62M | 16.76M | 4.36M | 1.25M | 956K |
| Research & Development | 64.6M | 145.86M | 172.92M | 141.89M | 90.57M | 80.14M | 95.95M | 89.45M | 81.99M | 38.09M | 10.72M | 4.8M | 2.08M |
| Other Expenses | 3.53M | n/a | 1M | -1.73M | 981K | 1.07M | 170K | 425K | n/a | n/a | n/a | n/a | n/a |
| Operating Expenses | 121.31M | 233.6M | 253.62M | 209.42M | 121.34M | 104.89M | 128.55M | 123.5M | 114.61M | 54.86M | 15.08M | 6.05M | 3.03M |
| Interest Expense | n/a | 13.18M | 6.02M | 2.91M | 2.92M | 502K | 1.17M | 1.59M | 969K | 555K | n/a | 42K | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | n/a | 234.31M | 253.62M | 209.42M | 121.34M | 104.89M | 128.55M | 123.5M | 114.61M | 54.86M | 15.08M | 6.05M | 3.03M |
| Income Tax | n/a | n/a | 3.67M | -4.08M | -2.67M | -6.04M | 1.34M | -1.59M | 2.23M | -804K | 1.63M | 42K | n/a |
| Shares Outstanding (Basic) | 155.4M | 128M | 108.08M | 91.7M | 79.79M | 56.65M | 40.74M | 40.45M | 39.85M | 23.53M | 29.78M | 29.78M | 20.68M |
| Shares Outstanding (Diluted) | 155.4M | 128M | 108.08M | 91.7M | 79.79M | 56.65M | 40.74M | 40.45M | 39.85M | 23.53M | 29.78M | 29.78M | 20.68M |
| EPS (Basic) | 0.00 | -0.89 | -2.35 | -0.67 | -1.08 | -1.13 | -2.43 | -2.21 | -2.3 | -2.33 | -0.56 | -0.2 | -0.15 |
| EPS (Diluted) | 0.00 | -0.89 | -2.35 | -0.67 | -1.08 | -1.13 | -2.43 | -2.21 | -2.3 | -2.33 | -0.56 | -0.2 | -0.15 |
| EBITDA | -121.31M | -94.31M | -237.51M | -56.72M | -77.31M | -59.95M | -91.08M | -82.12M | -88.63M | -54.13M | -14.89M | -5.96M | -3.01M |
| EBIT | n/a | -100.55M | -244.14M | -62.67M | -86.2M | -69.78M | -98.94M | -89.38M | -92.84M | -54.86M | -15.08M | -6.05M | -3.03M |
| Depreciation & Amortization | n/a | 6.24M | 11.85M | 9.22M | 8.89M | 9.83M | 7.86M | 7.26M | 4.21M | 728K | 190K | 88K | 25K |